Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) agreed to acquire Vega Therapeutics, a wholly owned Star Therapeutics subsidiary, for $1.25 billion upfront, plus up to $750 million in sales milestones, for potential consideration of $2.0 billion.
The deal adds VGA039, a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease, with multiple FDA designations. Closing is expected in Q3 2026, triggering an estimated $1.25 billion R&D charge to Incyte’s 2026 GAAP and non-GAAP results.
Incyte (Nasdaq: INCY) and Mirum Pharmaceuticals will present pivotal Phase 2 PROGRESS study results for investigational ALK2 inhibitor zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026 in Chicago, June 13-16, 2026.
The Cohort 1, placebo-controlled data supported the New Drug Application, which has an FDA Priority Review PDUFA date of September 26, 2026.
Incyte (Nasdaq: INCY) reported pivotal Phase 3 frontMIND results in previously untreated, high-risk DLBCL/HGBL. Adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP reduced risk of progression or death by 25% (HR 0.75, P=0.0194) versus R-CHOP alone.
Two-year PFS was 71.1% vs 62.9%; three-year PFS 67.3% vs 60.7%. Event-free survival improved (HR 0.79, P=0.0260). Interim overall survival showed a favorable trend (HR 0.85). Safety was manageable, though Grade ≥3 and fatal adverse events were higher with Tafa-Len-R-CHOP. The data support planned global regulatory submissions.
Incyte (Nasdaq: INCY) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT.
The presentation will be webcast live via Incyte's investor website and available for 30-day replay.
Incyte (Nasdaq: INCY) and Genesis Molecular AI expanded their collaboration to use Genesis’ GEMS molecular AI platform and Incyte’s proprietary experimental data to discover novel small-molecule drugs. Genesis receives $120M upfront ($80M cash, $40M equity), recurring research funding, and is eligible for up to $232M per program in milestones, over $1B across five initial targets, plus royalties, while Incyte gains exclusive rights to develop and commercialize collaboration products and options to nominate additional targets.
Incyte (Nasdaq: INCY) and Edison Scientific announced a strategic collaboration to deploy Edison’s Kosmos AI scientist platform across Incyte’s discovery and development lifecycle.
Kosmos will focus first on target discovery, validation and translational biology, continuously learning from translational and clinical data to support experimental design, evidence synthesis and long-term pipeline decision-making.
Incyte (Nasdaq: INCY) announced that more than 20 abstracts featuring its Hematology and Oncology portfolio have been accepted for presentation at the EHA 2026 Congress, held June 11–14, 2026 in Stockholm.
Highlights include pivotal Phase 3 frontMIND tafasitamab data in first-line DLBCL in a Plenary Session, and new clinical and preclinical results for INCA033989, INCA035784, INCB160058, axatilimab, ponatinib and ruxolitinib.
Incyte (Nasdaq:INCY) reported final Week 24 results from the Phase 3 TRuE-AD4 trial of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis who had inadequate response, intolerance or contraindication to TCSs/TCIs. Patients continuing as-needed treatment through Week 24 showed 84.3% EASI75 and 70.6% IGA-TS. Mean affected BSA remained 2.5%; itch NRS4 response was 64.7% at Week 24. Safety showed few application-site reactions (1.7%) and no new signals; most common TEAEs were URTI (10.6%) and nasopharyngitis (6.3%). Data support a Type-II variation application in the EU; feedback expected 1H 2026.
Incyte (Nasdaq:INCY) granted inducement equity awards to Suketu Upadhyay upon his hire as Executive Vice President and Chief Financial Officer, effective May 4, 2026.
The inducement includes 38,429 stock options, 26,343 RSUs, and 13,171 target performance shares. Options have a $97.14 exercise price equal to the closing price on the grant date and a ten-year term. Options vest 25% at one year, then monthly over three years; RSUs vest 25% annually over four years. Performance shares vest after a three-year period and may pay 0–200% of target based on relative TSR vs. a fixed peer group, with the performance period beginning January 1, 2026.
Specialised Therapeutics / Incyte (NASDAQ: INCY) announced TGA approval of NIKTIMVO (axatilimab) for chronic graft-versus-host disease (cGVHD) in patients ≥6 years and ≥40 kg after ≥2 prior systemic therapies. Approval followed Priority Review; Australia is the first country granted marketing authorisation after the US FDA decision.
The TGA decision relied on the AGAVE-201 trial (n=241) showing a 74% overall response rate at the approved 0.3 mg/kg biweekly dose and 60% durability at 12 months.